Arizona MPJE (Pharmacy Jurisprudence) Practice Exam 2025 - Free Pharmacy Law Practice Questions and Study Guide

Single-product ephedrine is classified as a Schedule III (CIII) controlled substance under federal law. This classification is due to its medicinal use as a stimulant and bronchodilator, and its potential for abuse or dependence. In particular, the single-entity preparation of ephedrine is regulated more closely due to its use in the illicit manufacturing of methamphetamine.

In considering other classifications, Schedule I (CI) substances are those with no accepted medical use, Schedule II (CII) substances are those with a high potential for abuse, leading to severe psychological or physical dependence, and Schedule IV (CIV) substances have a lower potential for abuse relative to those in Schedule III. Schedule V (CV) substances are subject to the lowest restrictions, typically with accepted medical uses and a lower potential for abuse.

Therefore, single-product ephedrine being classified under CIII reflects the balance between its therapeutic uses and the risks associated with its misuse. This distinction is essential for pharmacy practice, ensuring that pharmacists and healthcare providers handle and dispense it appropriately within legal guidelines.